

AWARD NUMBER: W81XWH-13-1-0486

TITLE: Early Recognition of Chronic Traumatic Encephalopathy Through FDDNP PET Imaging

PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, Ohio
44195

REPORT DATE: *October 2017*

TYPE OF REPORT: Annual

PREPARED FOR: U Army Med Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release
Distribution Unlimited

The opinions and/or findings contained in this report are those of author(s) should not be construed as an official Department of the Army position, policy or decision so by other documentation

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE October 2017			2. REPORT TYPE Annual		3. DATES COVERED 30Sept2016 - 29Sept2017	
4. TITLE AND SUBTITLE Early Recognition of Chronic Traumatic Encephalopathy Through FDDNP PET Imaging					5a. CONTRACT NUMBER	
					5b. CONTRACT NUMBER W81XWH-13-1-0486	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Charles Bernick, MD, MPH E-Mail: bernicc@ccf.org					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland, Ohio					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT						
1. The PET biomarker, F-FDDNP (2-(1-(6-[(2-[F-18]fluoroethyl(methyl)amino]-2-naphthyl)ethylidene)malononitrile) [FDDNP] has shown sensitivity for in vivo detection of tau in addition to β -sheet-containing brain amyloid neuroaggregates. Tau protein in a characteristic distribution is felt to be the cardinal pathologic feature of Chronic Traumatic Encephalopathy. This project will examine whether FDDNP PET imaging correlates with, and/or can predict, decline in cognitive function in those exposed to cumulative head trauma.						
15. SUBJECT TERMS Traumatic Brain Injury Positron Emission Tomography						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)	
Unclassified	Unclassified	Unclassified	Unclassified	9		

Table of Contents

	<u>Page</u>
1. Introduction.....	5
2. Keywords.....	5
3. Accomplishments	5
4. Impact.....	7
5. Changes/Problems.....	7
6. Products	8
7. Participants/Other Collaborators.. ..	8
8. Quad Chart	9


1. Introduction: Blast injuries and other head injuries sustained in battle have been associated with the development of chronic traumatic encephalopathy (CTE). Pathological series have indicated that a characteristic feature of CTE is accumulation of tau protein in the brain. Until very recently, there has been no reliable way of measuring tau deposition in the brain during life. One PET biomarker, F-FDDNP (2-(1-{6-[(2-[F-18]fluoroethyl(methyl)amino]-2-naphthyl) ethylidene) malononitrile) [FDDNP] has shown sensitivity for in vivo detection of tau in addition to B-sheet-containing brain amyloid neuroaggregates. This project will examine whether FDDNP PET imaging correlates with, and/or can predict, decline in cognitive function in those exposed to cumulative head trauma.

2. Keywords: Traumatic Brain Injury, Chronic Traumatic Encephalopathy, PET imaging, Tau

3. Accomplishments:

Major goals: Upon receiving approval from the Human Research Protection Office, enrollment of participants began in March, 2015. The major goal for 2017 was to complete enrollment; we finished enrollment in October, 2017, having completed 68 PET FDDNP studies.

Major accomplishments: Each subject is to be followed yearly for 3 years as part of the Professional Fighters Brain Health Study. Retention rate has been excellent. As of November, 2017 we have only 2 subjects who have been lost to follow up due to moving out of the country. Because of rolling enrollment over multiple years, follow up visits are staggered. The graph below indicates the number of subjects that have completed follow up visits, and the number who are overdue for their follow up (the reason the percentages do not add up to 100 is that some participants are not yet due for these follow ups). We are beginning to see our 3 year follow up visits now and the projected time for completion of all 3 year follow up visits is 4th quarter, 2020.



Interim analysis of data collected by the 3rd quarter of 2016 have been presented at two conferences in 2017 (see below). Using the automated MIAKAT (Imanova) kinetic analysis software, parametric images of distribution volume ratio (DVR) were generated with the cerebellum as the reference region. Regional DVR measurements were obtained using the built-in brain template with gray mask applied. 38 participants were included in the analysis (34 fighters, 4 controls) The results indicate a relationship between increased exposure to head trauma (measured by number of fights) and increased FDDNP uptake in the amygdala and other temporal lobe structures. However, uptake in these structures was also associated with age.

Table 1 - Regional uptake in ROIs with Age, Years of Pro Fighting, and Number of Pro Fights (Pearson’s correlations; ns – non significant)

Table 2: Uptake and exposure	Age	Years of Fighting	Number of Fights
amygdala,	.376*	ns	.412*
hippocampus	.330*	ns	.356*
parahippocampal gyrus	.ns	ns	.396*
brainstem	ns	ns	ns
temporal	.337*	ns	.434*
posterior cingulate	ns	ns	.346*
parietal	ns	ns	Ns
thalamus	ns	-.379*	Ns
basal ganglia	ns	ns	.391*

From these results, it became clear that age is an important modifying factor in interpreting PET FDDNP images; further analyses were postponed until we finished enrollment, which included additional older control subjects.

67 scans (49 fighters, 19 controls) have now been processed using automated PMOD software (one scan was not usable). The DVR results include PET motion correction and PET partial volume correction. We are currently running analyses examining correlations with PET regional uptake, exposure measures, and baseline MRI and clinical outcomes, controlling for age, race and education).

Training opportunities: This project has provided a training opportunity for our post –doctorate student, Bern Lee, who has worked on assessing the relationship between FDDNP imaging results and neuropsychological measures.

Dissemination of Results: Nothing to report

Future plans: Over the next 12 months, the investigators will be able to complete the one year follow ups on the entire cohort and complete two year follow up on close to two thirds of the cohort; we will have 3 year data on some subjects.. In addition, further interim analyses will be conducted to evaluate the correlations between:

- FDDNP PET binding and change over 1 or 2 year periods in clinical and imaging measures
- FDDNP PET binding and certain risk factors (extent of exposure to head trauma, genetics)
- FDDNP PET binding and multimodal MRI measures (in collaboration with ADMdx)
- FDDNP PET binding compared to AV 1451 ,another PET tau tracer that has been done on a subset of the cohort (in collaboration with Banner Alzheimer’s Institute)
- Association between clinician visual reads of the FDDNP scans and clinical status of the subject

4. Impact:

Impact on development of principal disciplines: At the current stage, the impact from this project is limited. However, the publication by Dr. Omalu and his group that reported the correlation between PET FDDNP binding and post-mortem findings in a retired NFL player has raised attention to this imaging method (Omalu B, et al. Postmortem Autopsy-Confirmation of Antemortem [F-18]FDDNP-PET Scans in a Football Player With Chronic Traumatic Encephalopathy. *Neurosurgery*. **2017** Nov 10. Epub ahead of print). In the case study, [F-18]FDDNP-PET binding levels correlated with brain tau deposition ($r_s = 0.59$, $P = .02$), with highest relative distribution volumes in the parasagittal and paraventricular regions of the brain

and the brain stem. Our study is one of the largest series using PET FDDNP imaging in individuals exposed to repetitive head trauma and followed over time. This puts the study in position to determine if certain binding patterns correlate with clinical symptoms and brain structural imaging over time.

Impact on other disciplines: Nothing to report

Impact on technology transfer: Nothing to report

Impact on society beyond science: Nothing to report

5 Changes/Problems:

Changes in approach: No changes in approach to report

Problems or delays: the major problem/delay that has occurred in this study has been the slow rate of recruitment. In 2017, we completed recruitment and all baseline FDDNP scans. We have received a no cost extension for 2018 to allow for the ongoing follow up of the cohort, as some of the most impactful information will be gained by determining the clinical and radiological trajectory of the subjects and the correlation with baseline PET FDDNP imaging

Changes that impact expenditures: None

Changes in care of human subjects: None. The study has received ongoing approval by the Cleveland Clinic IRB through 12/2/18.

6. Products:

The following conference presentations have been presented at national conferences:

Sarah J. Banks, Vladimir Kepe, Frank P. DiFilippo, Bern Lee Jorge Barrio, and Charles Bernick
Regional FDDNP Uptake and Exposure to Professional Fighting (Human Amyloid Imaging, Miami, 1/17)

Bern G. Lee, Charles Bernick, Vladimir Kepe, Frank P. DiFilippo, & Sarah J. Banks. [F-18]FDDNP Uptake, Neurocognition, and Number of Fights in Professional Boxers and MMA fighters (International Neuropsychology Society, New Orleans, 2/17)

No other products resulted from this study over the last year.

7. Participants and other Collaborating Organizations

The individuals who have worked on this project include:

Charles Bernick – no change

Sarah Banks – no change

Jorge Barrio - no change

Pamela Dino

Project role: research coordinator

Person month worked: 4

Contributions to project: Subject scheduling, conduct of study visit

Funding support – Cleveland Clinic

Change in active support: Nothing to report

Other organizations:

ADMdx, Chicago, Ill

Contribution: Analyses and interpretation of PET FDDNP imaging using machine learning methods and multimodal approaches.

Financial support: In – kind contribution of their staff time and facilities to analyze PET FDDNP images

8. Quad Chart:

Early Recognition of CTE through PET FDDNP Imaging PT120134



PI: Charles Bernick Org: Cleveland Clinic Award Amount: \$746,068


Study/Product Aim(s)

•Study Examine the performance of PET FDDNP in a group of active and retired professional boxers and non-trauma exposed controls.

•Outcomes To determine if PET FDDNP imaging may be a potential biomarker of and diagnostic tool for CTE.

Approach

- Cohort derived from the Professional Fighters Brain Health Study
- Active and retired boxers, both cognitively normal and cognitively impaired
- Subjects undergo baseline PET FDDNP imaging and followed annually with cognitive, behavioral, and neurological testing



Timeline and Cost

Activities	15	16	17	18	19	20
Baseline PET FDDNP		█	█			
Annual MRI, cognitive, behavioral assessments			█	█	█	█
Analysis				█	█	█
Estimated Budget (\$K)	\$304	\$302	\$140	\$0	\$0	\$0

Goals/Milestones

- CY13 Goal** – Develop SOP and train coordinator
- IRB Submission
 - Finalize logistics of transfer of FDDNP from production to site
- CY14 Goals** – IRB approval obtained, HRPO approval obtained, identified eligible subjects
- CY15 Goal** – Enrollment of subjects, 1st subject enrolled 3/15
- CY16 Goal** – Continue enrollment and begin annual follow up visits, analyses
- CY 17 Goal** – Complete enrollment and continue annual follow up visits, analyses
- CY 20 Goal** – Complete 3 year follow up visits on all subjects
- Comments/Challenges/Issues/Concerns**
- Delay in completion of service agreement/IRB approval/HRPO approval delayed initial enrollment. PET FDDNP imaging began 3/15. MRI scanner replacement slowed 2016 enrollment.